|Bid||1.2000 x N/A|
|Ask||1.2400 x N/A|
|Day's Range||1.1800 - 1.2400|
|52 Week Range||1.1800 - 1.7500|
|Beta (3Y Monthly)||-0.21|
|PE Ratio (TTM)||22.41|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Every investor in Delta 9 Cannabis Inc. (CVE:NINE) should be aware of the most powerful shareholder groups...
MedMen Enterprises (CSE: MMEN) (OTCQX: MMNFF) (FSE: A2JM6N) has entered into definitive agreements for a US$250 million secured convertible credit facility with Gotham Green Partners, an investor in the global cannabis industry. DELTA 9 CANNABIS (TSXV: NINE) (OTCQX: VRNDF) reported financial and operating results for the year ending December 31, 2018. Operating revenues was $7.57M for […]The post Cannabis Stock News Daily Roundup April 23 appeared first on Market Exclusive.
Cannabis News Listed securities of Supreme Cannabis Co. (TSXV: FIRE) (OTCQX: SPRWF) are expected to begin trading on the Toronto Stock Exchange on February 4, according to the company. At that time, Supreme Cannabis' common shares and 6.0% senior unsecured convertible debentures due 2021 will be voluntarily delisted from the TSX Venture Exchange and will […] The post Cannabis Stock News Daily Roundup February 4 appeared first on Market Exclusive.
Delta 9 Cannabis (OTCMKTS:VRNDF) has agreed to sell its 50% stake in the Delta West extraction facility to Westleaf (OTCMKTS:WSLFF). Under the agreement, Westleaf will issue 5,600,000 common shares in consideration for the acquisition of Delta 9's 50% stake in the project. The transaction is expected to close occur on or about January 31. "This […] The post Delta 9 Cannabis Agrees to Sell 50% Stake in Calgary Facility appeared first on Market Exclusive.
On August 29, Delta 9 (NINE.V), which is based in Manitoba, announced its second-quarter earnings a day after Tilray (TLRY) reported its second-quarter earnings. The company reported a 277% year-over-year increase in sales during the second quarter and a 210% year-over-year increase in sales in its first half of 2018. The management stated that Delta 9’s growth in sales was driven by an overall increase in registered patients from 1,657 to 3,052 as of June 30.